Key takeaway
What This Development Means
DEA has made permanent the Schedule I status of clonazolam, diclazepam, etizolam, flualprazolam and flubromazolam from 1 April 2026. Laboratories, suppliers and logistics teams that encounter these substances now need to confirm registration, security, inventory, transfer and disposal controls.
What does Schedule I placement mean for research organisations?
Schedule I placement does not prohibit research, but it makes authorisation and controls stricter. Research institutions typically need DEA registration, appropriate security, inventories, and recordkeeping. Projects involving analytical standards or pharmacology work should ensure approvals are in place and that any movement of materials uses compliant ordering and documentation processes.
Do companies need to take action before 1 April 2026?
Yes, if they handle any of the five substances. DEA states unregistered entities may not continue handling them unless registration is approved. Organisations unwilling or unable to register should arrange transfer to a registered party or compliant disposal in line with applicable laws. Review stock, shipping routes and import or export activities now.
Source basis: Federal Register, FR Doc. 2026-04112
The US Drug Enforcement Administration (DEA) has finalised Schedule I placement for five “designer benzodiazepines” by adding clonazolam, diclazepam, etizolam, flualprazolam and flubromazolam to Schedule I of the Controlled Substances Act (CSA). The final rule was published on 2 March 2026 and takes effect on 1 April 2026, making permanent the full set of Schedule I controls and sanctions for anyone handling these substances. (Federal Register FR Doc. 2026-04112, 91 FR 9985.)
What The Schedule I Placement Covers
The rule applies to the named substances and their salts and isomers where applicable. DEA describes them as central nervous system depressants structurally and pharmacologically related to classical benzodiazepines such as alprazolam, with effects including sedation, amnesia and respiratory depression.
For regulated organisations, the practical impact of Schedule I placement is that activities such as manufacture, distribution, reverse distribution, import, export, research, instructional activity, chemical analysis and possession now sit under Schedule I controls on an ongoing basis.
Why DEA Acted And What Changed From Temporary Controls
DEA previously issued a temporary Schedule I order on 26 July 2023, later extended until 26 July 2026. The new final rule converts those temporary controls into permanent scheduling following an HHS scientific and medical evaluation (June 2025) and DEA’s eight-factor analysis.
DEA cites three core Schedule I findings: high abuse potential, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. DEA also notes the action supports US obligations under the 1971 UN Convention on Psychotropic Substances, under which these substances were internationally scheduled.
Compliance Implications For Laboratories, Chemical Suppliers And Logistics
Organisations that may encounter reference standards or research materials should reassess controlled substance governance. DEA highlights requirements spanning registration, security, labelling and packaging, quota (for manufacturers), biennial inventories, records and reporting, and import and export controls.
A practical next step is to map any holdings and workflows involving these substances, confirm registration status where needed, and plan transfers or compliant disposal before the 1 April 2026 effective date.
Summary
DEA’s final rule confirms Schedule I placement for clonazolam, diclazepam, etizolam, flualprazolam and flubromazolam from 1 April 2026. The decision locks in strict, long-term US controls for handling and research, and raises the compliance bar for laboratories, suppliers and logistics teams that may store, test, ship or import these substances.
Related Articles
EU Overhauls Drug Precursor Regulation To Combat Designer Chemicals And Ease Compliance
EU launches new Regulation on drug precursors, targeting designer chemicals and reducing admin burden with digital systems for chemical industry compliance.
ACC Urges Congress To Seize Once-In-A-Decade TSCA Reform Opportunity
ACC is urging Congress to pursue targeted TSCA implementation reforms as EPA new chemical review delays and fee authority deadlines increase pressure on the programme.
USITC Expedited Review Puts R-32 Antidumping Duties Under Scrutiny
US antidumping duties on Chinese R-32 remain under review, keeping refrigerant sourcing, customs exposure and HVAC supply planning in focus.
